High dose rate transurethral brachytherapy as a boost dose for localized adenocarcinoma of the prostate

Serin M., Erkal H., SAK S., Cakmak A., Gogus O., Akkaya A.

UROLOGIA INTERNATIONALIS, cilt.58, sa.1, ss.30-33, 1997 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 58 Sayı: 1
  • Basım Tarihi: 1997
  • Doi Numarası: 10.1159/000282941
  • Dergi Adı: UROLOGIA INTERNATIONALIS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.30-33
  • Anahtar Kelimeler: adenocarcinoma, prostate, high dose rate transurethral, brachytherapy, prostate-specific antigen, radiotherapy, prostate, adenocarcinoma, TREATMENT-RELATED MORBIDITY, RADIATION-THERAPY, FOLLOW-UP, ANTIGEN, RADIOTHERAPY, CARCINOMA, CANCER, IRRADIATION, RTOG
  • Ankara Üniversitesi Adresli: Evet

Özet

From September 1989 to February 1993, 11 patients with localized adenocarcinoma of the prostate were treated with pelvic external-beam radiation therapy followed by high dose rate (HDR) transurethral brachytherapy as a boost dose. External-beam radiation therapy was administered through opposed pelvic fields using a Co-60 teletherapy unit to a tumor dose of 46-50 Gy in 23-25 fractions and followed by three fractions of transurethral brachytherapy, delivered using a Co-60 HDR remote afterloading equipment. The treatment time was calculated using the prostatic capsule as the reference point. The dose calculated to be delivered to the capsule was 5 Gy/fraction, making a total of 15 Cy. The follow-up period ranged from 11 to 65 months, with a median follow-up time of 30 months. Local. control was achieved in all patients. The prostate-specific antigen levels were normalized within 3 months of radiotherapy in 9 patients and within 3-6 months in the remaining 2. Transurethral brachytherapy appears to be a simple and feasible form of brachytherapy. Preliminary local control and radiotherapy-related morbidity rates are comparable to those of other forms of brachytherapy. Further follow-up is required for assessment of long-term local control and delayed radiotherapy-related morbidity.